Cancer Pain - Pipeline Review, H2 2018

Global Markets Direct
123 Pages - GMD17641
$2,000.00

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain - Pipeline Review, H2 2018, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape.

Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic and neurosurgical pain management.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Pain - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 8, 5, 15, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Cancer Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Cancer Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cancer Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cancer Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Pain (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cancer Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cancer Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

'

Table of Contents
Table of Contents 2
Introduction 5
Cancer Pain - Overview 6
Cancer Pain - Therapeutics Development 7
Cancer Pain - Therapeutics Assessment 15
Cancer Pain - Companies Involved in Therapeutics Development 24
Cancer Pain - Drug Profiles 38
Cancer Pain - Dormant Projects 101
Cancer Pain - Discontinued Products 105
Cancer Pain - Product Development Milestones 106
Appendix 117

List of Tables
Number of Products under Development for Cancer Pain, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Cancer Pain - Pipeline by Alexza Pharmaceuticals Inc, H2 2018
Cancer Pain - Pipeline by AngioChem Inc, H2 2018
Cancer Pain - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2018
Cancer Pain - Pipeline by Aphios Corp, H2 2018
Cancer Pain - Pipeline by AstraZeneca Plc, H2 2018
Cancer Pain - Pipeline by ChironWells GmbH, H2 2018
Cancer Pain - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018
Cancer Pain - Pipeline by Dompe Farmaceutici SpA, H2 2018
Cancer Pain - Pipeline by Fujimoto Pharmaceutical Corp, H2 2018
Cancer Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2018
Cancer Pain - Pipeline by Immupharma Plc, H2 2018
Cancer Pain - Pipeline by IntelGenx Corp, H2 2018
Cancer Pain - Pipeline by iX Biopharma Ltd, H2 2018
Cancer Pain - Pipeline by Klaria Pharma Holding AB, H2 2018
Cancer Pain - Pipeline by Komipharm International Co Ltd, H2 2018
Cancer Pain - Pipeline by Medlab Clinical Ltd, H2 2018
Cancer Pain - Pipeline by Nanomerics Ltd, H2 2018
Cancer Pain - Pipeline by Neurocentrx Pharma Ltd, H2 2018
Cancer Pain - Pipeline by Nippon Kayaku Co Ltd, H2 2018
Cancer Pain - Pipeline by Nippon Zoki Pharmaceutical Co Ltd, H2 2018
Cancer Pain - Pipeline by Oblique Therapeutics AB, H2 2018
Cancer Pain - Pipeline by Orion Corp, H2 2018
Cancer Pain - Pipeline by Pain Therapeutics Inc, H2 2018
Cancer Pain - Pipeline by Pfizer Inc, H2 2018
Cancer Pain - Pipeline by Pharmaleads SA, H2 2018
Cancer Pain - Pipeline by Plexxikon Inc, H2 2018
Cancer Pain - Pipeline by Recordati SpA, H2 2018
Cancer Pain - Pipeline by Ribomic Inc, H2 2018
Cancer Pain - Pipeline by Sorrento Therapeutics Inc, H2 2018
Cancer Pain - Pipeline by Tetra Bio-Pharma Inc, H2 2018
Cancer Pain - Pipeline by Virobay Inc, H2 2018
Cancer Pain - Pipeline by WEX Pharmaceuticals Inc, H2 2018
Cancer Pain - Dormant Projects, H2 2018
Cancer Pain - Dormant Projects, H2 2018 (Contd..1), H2 2018
Cancer Pain - Dormant Projects, H2 2018 (Contd..2), H2 2018
Cancer Pain - Dormant Projects, H2 2018 (Contd..3), H2 2018
Cancer Pain - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Cancer Pain, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838